Protagen and NMI announce Co-Development of Multiplex Assays
(PresseBox) - Protagen AG, a specialist in in-vitro diagnostics and the Natural and Medical Sciences Institute at the University of Tübingen (NMI), have announced the signing of an agreement for joint development of multiplex assays for the diagnosis of autoimmune diseases and cancer. The planned long-term partnership is based on results from pilot studies from the past two years and focuses on the development of customized assays for personalized medicin
"Protagen has a unique expertise in high-throughput expression of human proteins and the conduct of clinical validation studies for serum biomarkers. We also have an excellent network of internationally renowned clinical partners in the relevant indication areas ", explains Dr. Peter Schulz-Knappe, CSO and Executive Vice President of Diagnostics at Protagen. "Based on consistent enhancements of the UNIarray® concept and formation of a topclass partner network Protagen managed to position itself as an ideal partner for pharma and biotech drug developers
Professor Hugo Hämmerle, NMI, is also pleased with the intensification of the cooperation: "For several years our focus has been on development of testing systems using planar and bead-based protein microarrays. The competence and capability of our research platform was already validated by a number of projects with international partners from industry and academia. The cooperation with Protagen allows us to collaborate on the commercialization of assays for personalized medicine
About NMI, Natural and Medical Sciences Institute at the University of Tübingen, Reutling
The NMI (www.nmi.de) is an application-oriented research institute that makes the results of scientific study available to industry. The interdisciplinary approach of the NMI includes basic research as well as practical problem solving in the form of applied research and development, consultancy, testing, measuring and analysis, scientific studies, and implementation in the fields of pharma- and biotechnology, biomedical technology as well as surface and interface technologies. The NMI makes use of interdisciplinary know-how, modern equipment, quality management processes and a network of companies including various branches of industry, in particular the life sciences.
Protagen (www.protagen.com) is an internationally leading specialist in the field of in vitro diagnostics and GMP-compliant protein analysis. The business unit Diagnostics employs its proprietary UNIarray® technology to develop diagnostic tests and for collaborations with pharmaceutical and biotech companies in the field of personalized medicine. The business unit Protein Services is a world leading service provider of GMP-compliant characterization and comparability studies of biotherapeutics and biosimilar
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Protagen (www.protagen.com) is an internationally leading specialist in the field of in vitro diagnostics and GMP-compliant protein analysis. The business unit Diagnostics employs its proprietary UNIarray® technology to develop diagnostic tests and for collaborations with pharmaceutical and biotech companies in the field of personalized medicine. The business unit Protein Services is a world leading service provider of GMP-compliant characterization and comparability studies of biotherapeutics and biosimilar
Datum: 15.03.2012 - 07:14 Uhr
Sprache: Deutsch
News-ID 1093130
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Dortmund
Phone:
Kategorie:
Electronics & Semiconductors
Anmerkungen:
Diese Pressemitteilung wurde bisher 261 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Protagen and NMI announce Co-Development of Multiplex Assays
"
steht unter der journalistisch-redaktionellen Verantwortung von
Protagen AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
